Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.
dc.contributor.author | Mandala, Mario | |
dc.contributor.author | Fornaro, Lorenzo | |
dc.contributor.author | Olesinski, Tomasz | |
dc.contributor.author | Caglevic, Christian | |
dc.contributor.author | Chung, Hyun Cheol | |
dc.contributor.author | Muro, Kei | |
dc.contributor.author | Van Cutsem, Eric | |
dc.contributor.author | Elme, Anneli | |
dc.contributor.author | Thuss-Patience, Peter C. | |
dc.contributor.author | Chau, Ian | |
dc.contributor.author | Ohtsu, Atsushi | |
dc.contributor.author | Bhagia, Pooja | |
dc.contributor.author | Wang, Anran | |
dc.contributor.author | Shih, Chie-Schin | |
dc.contributor.author | Shitara, Kohei | |
dc.contributor.author | Fuchs, Charles S. | |
dc.contributor.author | Ozguroglu, Mustafa | |
dc.contributor.author | Bang, Yung-Jue | |
dc.contributor.author | Di Bartolomeo, Maria | |
dc.contributor.author | Ryu, Min-hee | |
dc.date.accessioned | 2021-03-02T18:31:24Z | |
dc.date.available | 2021-03-02T18:31:24Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Fuchs C. S. , Ozguroglu M., Bang Y., Di Bartolomeo M., Mandala M., Ryu M., Fornaro L., Olesinski T., Caglevic C., Chung H. C. , et al., "Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.", JOURNAL OF CLINICAL ONCOLOGY, cilt.38, 2020 | |
dc.identifier.issn | 0732-183X | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_b905d45f-23f1-4092-b2b5-7d49556cac81 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/5087 | |
dc.language.iso | eng | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ONKOLOJİ | |
dc.title | Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial. | |
dc.type | Makale | |
dc.relation.journal | JOURNAL OF CLINICAL ONCOLOGY | |
dc.contributor.department | , , | |
dc.identifier.volume | 38 | |
dc.identifier.issue | 15 | |
dc.contributor.firstauthorID | 2281572 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
Makale [92796]